Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Versant Futures

- PMLiVE

Biogen grows in Q2, but Spinraza performance a concern

Company banking on pipeline readouts and Tecfidra defence

- PMLiVE

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Strengthens existing relationship

- PMLiVE

Scancell preps phase 2 challenge for melanoma vaccine

Progress continues for biotech

- PMLiVE

UK financial authority confirms Woodford probe

Biotech investor in cross-hairs

- PMLiVE

Twentyeight-Seven raises another $15m for non-coding RNA drugs

Adds to funds raised from pharma venture units

Bayer symbol

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga

- PMLiVE

Alector kicks off next wave of biotech IPOs

US biotech raising money again

- PMLiVE

UK biotech booms in 2018, despite Brexit worries

Industry attracted a record-breaking £2.2bn in investment last year

- PMLiVE

Moderna CEO makes case for firm’s lofty valuation

mRNA specialist has to convince investors after stocks slide

- PMLiVE

After December slump, what’s in store for biotech in 2019?

Analysts say 2019 could be a "big year for proceeds if not for deal count"

Navigating the antibiotic resistance crisis

Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Blue Latitude Health

Report: Achieving launch excellence in the challenging healthcare markets of today

Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links